Psoriatic Arthritis Diagnostic Test Grant

PsA is a serious illness that can result in joint destruction if left untreated. People with PsA experience pain, joint stiffness and swelling, and extreme fatigue.

 
Two people working on a computer in a lab

While Psoriatic arthritis (PsA) can start at any age, it often presents in patients between the ages of 30 and 50 years. On average, symptoms begin to present approximately 10 years after a psoriasis diagnosis. While it is less common, people can develop PsA without having psoriasis.

Early recognition, diagnosis, and treatment of PsA are critical to relieving pain and inflammation and helping to prevent joint damage. Furthermore, delaying treatment by as little as six months can result in permanent joint damage, according to studies.

The PsA treatments we have currently were barely a dream a generation ago. But curing PsA remains such a dream. One big reason: the lack of a diagnostic test. NPF launched the PsA Diagnostic Test Grant to fill that gap.

This grant program funded six first-year, proof-of-concept proposals that have the potential to achieve this goal within five years. Grant recipients include Vinod Chandran, M.B., B.S., M.D., D.M., Ph.D.; Bingjian Feng, Ph.D.; Wilson Liao, M.D.; Ananta Paine, Ph.D.; Siba Raychaudhuri, M.D.; and Jose Scher, M.D.

Following a 1-year, $100,000 extension, awardees underwent a competitive renewal application for subsequent funding. Due to the high caliber of preliminary data and project submissions, NPF awarded two meritorious applicants, Vinod Chandran, M.B., B.S., M.D., D.M., Ph.D.; and Jose Scher, M.D. Competitive renewal awardees will receive $300,000 per year, for years 3 – 5 of the projects, contingent on satisfactory progress.

Currently Funded Projects

  • Multi-omic Diagnostic Test for Psoriatic Arthritis in Psoriasis Patients
    Vinod Chandran, M.B., B.S., M.D., D.M., Ph.D.
    University Health Network
  • Investigating Cellular and Molecular-Based Biomarkers of Disease Progression in Psoriatic Arthritis
    Jose Scher, M.D.
    New York University School of Medicine

NPF is determined to contribute to the creation of a PsA diagnostic test as the first step on the road to a cure. A diagnostic test will dramatically reduce the guesswork and the long delays in reaching a diagnosis and beginning treatment.

Driven by NPF’s 2020-2024 strategic plan, the PsA project, of which the PsA Diagnostic Test Grant is a part, focuses on four areas of impact:

  • Decreasing the time to diagnosis
  • Helping those with PsA better manage their disease
  • Reducing barriers to health care and treatments
  • Improving understanding of PsA symptoms, disease management, and impact on patient quality of life among health care providers
Illustration of a doctor and medical researchers.

Psoriatic Arthritis: Where We Are and Where We’re Going

Where we stand and a glimpse of the road ahead.

Read more
A graphic of a woman sitting with the text "Do I have psoriatic arthritis? These 5 questions could change your life."

Screen for PsA

Fortunately, validated screening tools exist to help identify signs and symptoms of PsA.

Screen now

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.